Search Results 791-800 of 10462 for total t4
Participation eligibility · Hemoglobin ≥ 9.0 g/dL · Absolute neutrophil count (ANC) ≥ 1500/mm3 · Platelet count ≥ 100,000/mm3 · Total bilirubin ≤ 1.5 x ULN.
Simon Laplante, M.D., Metabolic Surgeon, Mayo Clinic: Obesity is a very chronic condition. It's a very complex condition that affects multiple systems in ...
More complete tumor removal. When surgeons can safely remove most or all the ... Younger age and good overall health. Younger people and those with ...
... total hip replacement, Infected total knee replacement, Benign bone tumor, Failed total hip replacement, Failed total knee replacement, Pathologic ...
The total duration of a subject's participation will be up to 45 days of screening and 24 weeks of study including follow-up. Biobank for Cholestatic Liver ...
... total knee replacement, Failed total hip replacement, Failed back syndrome, Radiculopathy, Neuropathic pain syndrome. Show more areas of focus for Ryan S. D ...
Key secondary endpoints are toxicity, end-Induction response, and overall survival. Late effects of therapy including targeted therapies will be compared ...
... total bilirubin levels > 1.5 ULN OR total bilirubin ≤2 X ULN if liver metastases are present ... Replacement therapy (eg., thyroxine, insulin, or ...
Age 16 to < 18 years > Male 1.7 | Female 1.4. Hepatic; Total bilirubin; Participants with Gilbert's Syndrome (only if direct bilirubin ≤ 35%) | ≤ 1.5 x ULN ...
Additionally, to compare the effectiveness of axicabtagene ciloleucel versus SOCT, as measured by progression-free survival (PFS) and overall survival (OS).
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.